sb 203580 has been researched along with alprenolol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (alprenolol) | Trials (alprenolol) | Recent Studies (post-2010) (alprenolol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,146 | 121 | 59 |
| Protein | Taxonomy | sb 203580 (IC50) | alprenolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0031 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.007 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.63 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 0.0023 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0049 | |
| Squalene synthase | Rattus norvegicus (Norway rat) | 4.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genade, S; Lochner, A; Marais, E; Moolman, JA; Strijdom, H | 1 |
1 other study(ies) available for sb 203580 and alprenolol
| Article | Year |
|---|---|
p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alprenolol; Animals; Enzyme Activation; Enzyme Inhibitors; Imidazoles; Ischemic Preconditioning, Myocardial; Isoproterenol; Male; Mitogen-Activated Protein Kinases; Myocardial Ischemia; Myocardial Reperfusion; p38 Mitogen-Activated Protein Kinases; Perfusion; Phosphorylation; Pyridines; Rats; Rats, Wistar; Receptors, Adrenergic, beta | 2001 |